Amgen

We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.

We live the mission.

We win together.

We thrive on continual challenge.

Our team of 27,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.

At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.

Connect with us to explore how you can Win, Live, and Thrive at Amgen.

AWARDS
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
  • amgen forbes award.png
  • amgen fortune award.png
  • amgen innovative award.png
  • amgen diversity award.png
Corporate Headquarters
One Amgen Center Drive
Thousand Oaks, CA 91320
  • Featured Employer Badge
We know an idea—any idea—can blossom into a lifesaving treatment. That’s why we dare to ask the questions most people won’t. Join us in pushing biotechnology.
Employee Testimonials
  • “Amgen fosters a culture of innovation, with a science-based risk approach, centered in the benefit of our patients and powered by the diversity of our staff.”
    Jorge D.
    Porcess Scientific Director
    Juncos, PR
  • “Cultivate your curiosity and continue to learn at Amgen — grow daily and explore career opportunities that align with your competencies and motivation”
    Fernando F.
    Executive Director Plant Manager
    Rhode Island, US
  • “Working at Amgen, as Specialist Quality Control gives me the opportunity to work with Amgen products in benefit of the patients. Using my knowledge in science and share my diversity with my peers, is the best experience I have as part of the Amgen family.”
    Niria R.
    Specialist Quality Control
    Juncos, PR
Serving patients across the globe requires a global team. We continue building a diverse workforce that reflects the needs of those they serve, bringing with them innovative ideas that can push biotechnology forward.
We offer more than benefits. Our Total Rewards Program secures the long-term financial, physical and overall well-being of you and your family. Among leading biotechnology and pharmaceutical leaders, we stand among the very best.
Through Amgen Volunteers, you can dedicate eight hours to participating organizations of your choice. This along with matching employee donations to charities and our diverse corporate giving initiatives are just some ways you can make meaningful contributions as a global citizen
Amgen is proud of the achievements we have realized as a mission-driven team—particularly the accolades we have earned as an employer. You can find our teams named in respected lists including Forbes, Fast Company and more.
NEWS
The discovery of a unique, inheritable resistance to Ebola infection has inspired the development of therapeutics that may not only be effective against Ebola but against COVID-19, as well.
AbbVie and Alvotech have settled a case, granting Alvotech a non-exclusive license to all Humira-related patents in the United States beginning on July 1, 2023.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
Plexium raised millions for its multi-year research collaboration and license deal with Amgen to identify novel targeted protein degradation therapeutics.
Much of Amgen’s modest gains in the year can be attributed to its manufacturing partnership with Eli Lilly and an increase in sales for EVENITY.
The collaboration will focus on expanding targeted protein degradation therapies through the discovery of previously unrecognized molecular glues or monovalent degraders.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
JOBS
IN THE PRESS